17. Remission analysis 2 (MTX/DMARD active comparator) for the type of medication: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| TNF | MTX/other DMARD | 2.11 (1.29, 3.54) | 1.96 (1.27, 3.04) | 0.07 (0.02, 0.14) |
| Non‐TNF | 4.59 (2.08, 10.27) | 3.66 (1.93, 6.36) | 0.19 (0.07, 0.36) | |
| MTX + TNF | 4.09 (2.91, 5.93) | 3.36 (2.54, 4.50) | 0.17 (0.11, 0.23) | |
| MTX + non‐TNF | 4.71 (3.02, 7.60) | 3.73 (2.62, 5.32) | 0.19 (0.12, 0.28) | |
| MTX + TOFA | 8.15 (1.66, 49.85) | 5.40 (1.58, 11.79) | 0.31 (0.04, 0.71) | |
| Non‐TNF | TNF | 2.17 (0.94, 4.93) | 1.87 (0.95, 3.38) | 0.12 (‐0.01, 0.28) |
| MTX + TNF | 1.93 (1.22, 3.09) | 1.71 (1.17, 2.56) | 0.10 (0.03, 0.16) | |
| MTX + non‐TNF | 2.23 (1.20, 4.17) | 1.90 (1.16, 3.17) | 0.12 (0.03, 0.23) | |
| MTX + TOFA | 3.85 (0.72, 25.04) | 2.74 (0.76, 6.70) | 0.24 (‐0.04, 0.65) | |
| MTX + TNF | Non‐TNF | 0.89 (0.40, 2.05) | 0.92 (0.53, 1.78) | ‐0.02 (‐0.20, 0.11) |
| MTX + non‐TNF | 1.02 (0.48, 2.23) | 1.02 (0.61, 1.88) | 0.00 (‐0.16, 0.13) | |
| MTX + TOFA | 1.78 (0.30, 12.74) | 1.47 (0.39, 4.02) | 0.12 (‐0.21, 0.55) | |
| MTX + non‐TNF | MTX + TNF | 1.15 (0.69, 1.93) | 1.11 (0.75, 1.62) | 0.03 (‐0.07, 0.13) |
| MTX + TOFA | 1.99 (0.39, 12.55) | 1.61 (0.46, 3.60) | 0.14 (‐0.14, 0.56) | |
| MTX + TOFA | MTX + non‐TNF | 1.73 (0.33, 11.10) | 1.45 (0.41, 3.34) | 0.12 (‐0.17, 0.53) |
| Random‐effects model | Residual deviance | 64.66 vs 63 data‐points | ||
| Deviance information criteria | 409.045 | |||
| Fixed‐Effect Model | Residual deviance | 134.2 vs 63 data‐points | ||
| Deviance information criteria | 459.699 | |||
| Note | ||||
| Total participants | 12668 | |||
| Total studies | 29 | |||
| 2‐arm | 24 | |||
| 3‐arm | 5 |